RegCell's Groundbreaking Research on Antigen-Specific Tolerance Paves the Way for Autoimmune Disease Treatment RegCell has announced two crucial peer-reviewed studies demonstrating the potential of antigen-specific tolerance in treating autoimmune diseases through T cell reprogramming.

RegCell's Groundbreaking Research on Antigen-Specific Tolerance Paves the Way for Autoimmune Disease Treatment #USA #Emeryville #RegCell #Shimon_Sakaguchi #Tregs

坂口志文教授がノーベル医学賞受賞！免疫学に新たな地平を切り開く 坂口志文教授がノーベル生理学・医学賞を受賞。免疫学の革新者として、自己免疫疾患治療に新たな突破口を開きました。

坂口志文教授がノーベル医学賞受賞！免疫学に新たな地平を切り開く #グローバル・ブレイン #坂口志文 #RegCell

坂口志文教授がノーベル生理学・医学賞を受賞。免疫学の革新者として、自己免疫疾患治療に新たな突破口を開きました。

Dr. Shimon Sakaguchi Receives Nobel Prize for Revolutionary Treg Discoveries in Medicine RegCell's co-founder, Dr. Shimon Sakaguchi, has been honored with the 2025 Nobel Prize in Physiology for his vital contributions to immunology.

Dr. Shimon Sakaguchi Receives Nobel Prize for Revolutionary Treg Discoveries in Medicine #United_States #Emeryville #Nobel_Prize #RegCell #Shimon_Sakaguchi

RegCell's New Funding and Headquarters Move Signals Growth in Immune Therapeutics Japanese biotech company RegCell has secured $45.8 million in funding to advance innovative T-cell therapies, transitioning to a U.S. base for further development.

RegCell's New Funding and Headquarters Move Signals Growth in Immune Therapeutics #United_States #biotech #Emeryville #Immunology #RegCell